Authors:
Hejdeman, B
Lenkei, R
Leandersson, AC
Hultstrom, AL
Wahren, B
Sandstrom, E
Bratt, G
Citation: B. Hejdeman et al., Clinical and immunological benefits from highly active antiretroviral therapy in spite of limited viral load reduction in HIV type 1 infection, AIDS RES H, 17(4), 2001, pp. 277-286
Authors:
O'Meara, D
Wilbe, K
Leitner, T
Hejdeman, B
Albert, J
Lundeberg, J
Citation: D. O'Meara et al., Monitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing, J CLIN MICR, 39(2), 2001, pp. 464-473
Authors:
De Milito, A
Hejdeman, B
Albert, J
Aleman, S
Sonnerborg, A
Zazzi, M
Chiodi, F
Citation: A. De Milito et al., High plasma levels of soluble Fas in HIV type 1-infected subjects are not normalized during highly active antiretroviral therapy, AIDS RES H, 16(14), 2000, pp. 1379-1384
Authors:
Hulstrom, AL
Hejdeman, B
Leandersson, AC
Bratt, G
Carbone, E
Wahren, B
Citation: Al. Hulstrom et al., Human natural killer cells in asymptomatic human immunodeficiency virus-1 Infection, INTERVIROLO, 43(4-6), 2000, pp. 294-301
Authors:
Van Vaerenbergh, K
Van Laethem, K
Albert, J
Boucher, CAB
Clotet, B
Floridia, M
Gerstoft, J
Hejdeman, B
Nielsen, C
Pannecouque, C
Perrin, L
Pirillo, MF
Ruiz, L
Schmit, JC
Schneider, F
Schoolmeester, A
Schuurman, R
Stellbrink, HJ
Stuyver, L
Van Lunzen, J
Van Remoortel, B
Van Wijngaerden, E
Vella, S
Witvrouw, M
Yerly, S
De Clercq, E
Desmyter, J
Vandamme, AM
Citation: K. Van Vaerenbergh et al., Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues, ANTIM AG CH, 44(8), 2000, pp. 2109-2117